In a significant strategic pivot, telehealth provider Hims & Hers has announced a direct partnership with pharmaceutical giant Novo Nordisk. The collaboration will enable the company to offer FDA-approved GLP-1 medications, including Ozempic and Wegovy, marking a definitive shift away from its previous reliance on compounded drug formulations.
A Strategic Realignment Amid Regulatory Scrutiny
The move resolves a period of legal and regulatory uncertainty for Hims & Hers. The company had previously built its weight-management service around compounded versions of popular weight-loss drugs—custom-mixed formulations that have faced increasing regulatory pressure. Novo Nordisk itself had initiated legal proceedings against the telehealth firm over this practice. Those lawsuits have now apparently been dropped, clearing the path for this new commercial agreement.
By aligning directly with one of the world’s largest pharmaceutical manufacturers, Hims & Hers substantially reduces the regulatory risk that accompanied its former compounding model. This establishes the company’s weight-management business on a more stable foundation and repositions it as an authorized distribution channel for established brand-name products.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Market Access and Competitive Dynamics
The intensifying competition in the lucrative GLP-1 drug segment is underscored by this deal. Telehealth platforms that continue to depend on legally ambiguous compounded alternatives are increasingly placed at a competitive disadvantage. Hims & Hers has proactively secured its position by establishing a direct supply line to the original manufacturer.
Operational steps are already underway. On March 18, 2026, Hims & Hers opened a waiting list for patient access to the medications. The list covers both oral and injectable forms of Wegovy, as well as Ozempic injections, across all available dosage strengths. The official launch and full availability of the products through its platform are now imminent.
This partnership fundamentally alters Hims & Hers’s standing in the market, granting it a level of legitimacy and supply-chain security that was absent under its previous approach. The company’s core business model has undergone a substantial transformation as a result.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from March 19 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 19.
Hims & Hers: Buy or sell? Read more here...
